In addition to our product candidates custirsen in Phase 3 development, and OGX-427 in Phase 2 development, our investigational compound OGX-225 is in pre-clinical development.
OGX-225 is a second generation antisense drug candidate designed to inhibit the production of Insulin Growth Factor Binding Proteins -2 and -5 (IGFBP-2, IGFBP-5), two proteins that when overexpressed affect the growth of cancer cells.
Increased IGFBP-2 and IGFBP-5 production are observed in many human cancers, including prostate, breast, colorectal, non-small cell lung, glioblastoma, acute myeloid leukemia, acute lymphoblastic leukemia, neuroblastoma, and melanoma.
Increased IGFBP-2 and IGFBP-5 production are linked to faster rates of cancer progression, treatment resistance, and shorter survival duration in humans.
Preclinical studies with human prostate and breast cancer cells have shown that reducing IGFBP-2 and IGFBP-5 production with OGX-225 sensitized these tumor types to hormone ablation therapy or chemotherapy and induced tumor cell death.
This section is intended specifically for health care professionals. Information is provided for educational use only, based on pre-clinical and clinical data of custirsen and OGX-427. Custirsen and OGX-427 are not approved for commercial use and are only available for investigational use in approved clinical trials.